A Pilot Study to Evaluate the Role of High-dose Ranibizumab (2.0mg) in the Management of AMD in Patients With Persistent/Recurrent Macular Fluid Less Than 30 Days Following Treatment With Intravitreal Anti-VEGF Therapy (the LAST Study)

Exclusion Criteria

• •Subjects who meet any of the following criteria will be excluded from this study:
• •Pregnancy (positive pregnancy test) or lactation
• •Premenopausal women not using adequate contraception. The following are considered effective means of contraception: surgical sterilization or use of oral contraceptives, barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel, an IUD, or contraceptive hormone implant or patch.
• •Participation in another simultaneous medical investigation or trial
• •Prior treatment with anti-VEGF therapy in the study eye within 30 days of BSL
• •Prior treatment with triamcinolone in the study eye within 6 months of BSL.
• •Prior treatment with dexamethasone in the study eye within 30 days prior to BSL
• •Past treatment with PDT or thermal laser in the study eye
• •Intraocular surgery (including cataract surgery) in the study eye within 2 months preceding BSL
• •History of vitrectomy surgery, submacular surgery, or other surgical intervention for AMD in the study eye
• •Active intraocular inflammation (grade trace or above) in the study eye
• •Current vitreous hemorrhage in the study eye
• •History of rhegmatogenous retinal detachment or macular hole (Stage 3 or 4) in the study eye
• •Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye
• •Uncontrolled glaucoma in the study eye (defined as IOP ≥ 30 mmHg despite treatment with anti-glaucoma medication)
• •History of cerebral vascular accident, myocardial infarction, transient ischemic attacks within 3 months of study enrollment.
• •History of allergy to fluorescein, not amenable to treatment